Insider Transactions in Q1 2024 at Eye Point Pharmaceuticals, Inc. (EYPT)
Insider Transaction List (Q1 2024)
| Date | Insider | Transaction | Ownership Type | Shares Traded | Value / Price |
|---|---|---|---|---|---|
|
Jan 06
2024
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
5,966
-30.4%
|
$119,320
$20.4 P/Share
|
|
Jan 06
2024
|
Michael Craig Pine Chief Corp Dev.&Strat. Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+43.78%
|
-
|
|
Jan 06
2024
|
Jay S. Duker President and CEO |
SELL
Payment of exercise price or tax liability
|
Direct |
6,528
-13.05%
|
$130,560
$20.4 P/Share
|
|
Jan 06
2024
|
Jay S. Duker President and CEO |
BUY
Exercise of conversion of derivative security
|
Direct |
20,793
+29.37%
|
-
|
|
Jan 06
2024
|
David Scott Jones SVP & Chief Commercial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,147
-9.85%
|
$82,940
$20.4 P/Share
|
|
Jan 06
2024
|
David Scott Jones SVP & Chief Commercial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+26.63%
|
-
|
|
Jan 06
2024
|
George Elston Chief Financial Officer |
SELL
Payment of exercise price or tax liability
|
Direct |
4,911
-12.21%
|
$98,220
$20.4 P/Share
|
|
Jan 06
2024
|
George Elston Chief Financial Officer |
BUY
Exercise of conversion of derivative security
|
Direct |
15,285
+27.54%
|
-
|